S. Rose

发表

Programmed Death-1 Blockade With Pembrolizumab in Patients With Classical Hodgkin Lymphoma After Brentuximab Vedotin Failure.

M. Shipp, P. Zinzani, P. Armand, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Cyanotic Congenital Heart Disease (CCHD) with Symptomatic Erythrocytosis

D. Hoover, P. Saidi, S. Rose, 2007, Journal of General Internal Medicine.

Phase I Study Evaluating WEE1 Inhibitor AZD1775 As Monotherapy and in Combination With Gemcitabine, Cisplatin, or Carboplatin in Patients With Advanced Solid Tumors.

A. Oza, G. Shapiro, J. Schellens, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Fedratinib in patients with myelofibrosis previously treated with ruxolitinib: An updated analysis of the JAKARTA2 study using stringent criteria for ruxolitinib failure

S. Verstovsek, R. Mesa, M. Talpaz, 2020, American journal of hematology.

The Effect of Fedratinib, A Selective Inhibitor of Janus Kinase 2, on Weight and Metabolic Parameters in Patients with Intermediate- or High-risk Myelofibrosis.

J. Mascarenhas, O. Sy, S. Rose, 2022, Clinical lymphoma, myeloma & leukemia.

A randomized phase 2 trial of azacitidine with or without durvalumab as first-line therapy for older patients with AML

M. Tormo, M. Voso, J. Cavenagh, 2021, Blood advances.

Safety and efficacy of fedratinib, a selective oral inhibitor of Janus kinase‐2 (JAK2), in patients with myelofibrosis and low pretreatment platelet counts

S. Verstovsek, R. Mesa, M. Talpaz, 2022, British journal of haematology.

Updated results of the placebo‐controlled, phase III JAKARTA trial of fedratinib in patients with intermediate‐2 or high‐risk myelofibrosis

A. Vannucchi, A. Tefferi, C. Harrison, 2021, British journal of haematology.

A phase 1 (Ph1) trial of MK-3475 combined with lenalidomide (Len) and low-dose dexamethasone (Dex) in patients (pts) with relapsed/refractory multiple myeloma (RRMM).

D. Siegel, J. Miguel, M. Dolled-Filhart, 2014 .

A multicohort trial of the safety and efficacy of the PD-1 inhibitor MK-3475 in patients with hematologic malignancies.

M. Dolled-Filhart, K. Emancipator, P. Zinzani, 2014 .

A phase I trial of the human double minute 2 inhibitor (MK-8242) in patients with refractory/recurrent acute myelogenous leukemia (AML).

M. Minden, H. Kantarjian, F. Ravandi, 2015, Leukemia research.

Phase II Study of WEE1 Inhibitor AZD1775 Plus Carboplatin in Patients With TP53-Mutated Ovarian Cancer Refractory or Resistant to First-Line Therapy Within 3 Months.

D. de Jong, J. Schellens, J. Beijnen, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A Biomarker-enriched, Randomized Phase II Trial of Adavosertib (AZD1775) Plus Paclitaxel and Carboplatin for Women with Platinum-sensitive TP53-mutant Ovarian Cancer

A. Oza, R. Wenham, D. Provencher, 2020, Clinical Cancer Research.

Phase I Trial of the Human Double Minute 2 Inhibitor MK-8242 in Patients With Advanced Solid Tumors.

D. Hong, U. Banerji, N. Somaiah, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Abscopal effect in a Hodgkin lymphoma patient treated by an anti-programmed death 1 antibody.

Eric Deutsch, Laurent Dercle, Renaud Mazeron, 2016, European journal of cancer.

PD-1 Blockade with the Monoclonal Antibody Pembrolizumab (MK-3475) in Patients with Classical Hodgkin Lymphoma after Brentuximab Vedotin Failure: Preliminary Results from a Phase 1b Study (KEYNOTE-013)

M. Shipp, P. Zinzani, G. Martinelli, 2014 .

A Randomized, Phase 3 Trial of Fedratinib Versus Best Available Therapy in Patients with Intermediate-2 or High-Risk Myelofibrosis Previously Treated with Ruxolitinib (FREEDOM2)

S. Verstovsek, R. Mesa, G. Barosi, 2021, Blood.

Red Blood Cell Exchange Transfusion (RBCET) in the Management of Acute Hemolytic Transfusion Reaction (AHTR).

S. Rose, M. Kuriyan, Serena Wong, 2007 .

Fedratinib Improves Myelofibrosis-related Symptoms and Health-related Quality of Life in Patients with Myelofibrosis Previously Treated with Ruxolitinib: Patient-reported Outcomes from the Phase II JAKARTA2 Trial

S. Verstovsek, R. Mesa, M. Talpaz, 2021, HemaSphere.

Patient-reported Effects of Fedratinib, an Oral, Selective Inhibitor of Janus Kinase 2, on Myelofibrosis-related Symptoms and Health-related Quality of Life in the Randomized, Placebo-controlled, Phase III JAKARTA Trial

S. Verstovsek, R. Mesa, M. Talpaz, 2021, HemaSphere.

Fedratinib Induces Spleen Responses and Reduces Symptom Burden as First-line or Salvage Therapy in Patients with Myeloproliferative Neoplasm-Associated Intermediate- or High-Risk Myelofibrosis (MF) and Low Platelet Counts

S. Verstovsek, T. Gerike, R. Mesa, 2019, Clinical Lymphoma, Myeloma & Leukemia.

Fedratinib, an Oral, Selective Inhibitor of Janus Kinase 2 (JAK2), in Patients with Intermediate-2 or High-Risk Myelofibrosis (MF): Updated Results from the Randomized, Placebo-Controlled, Phase III JAKARTA Trial

A. Vannucchi, A. Tefferi, C. Harrison, 2020 .

S. Verstovsek, R. Mesa, M. Talpaz, 2019, Blood.

Fedratinib Induces Spleen Responses in Patients with Myeloproliferative Neoplasm (MPN)-Associated Intermediate- or High-Risk Myelofibrosis (MF) Resistant or Intolerant to Ruxolitinib: An Updated Analysis of the Phase II JAKARTA2 Study

S. Verstovsek, T. Gerike, R. Mesa, 2019, Clinical Lymphoma Myeloma and Leukemia.

Population Pharmacokinetics of an Anti-PD-L1 Antibody, Durvalumab in Patients with Hematologic Malignancies

M. Czuczman, V. Komashko, S. Zhou, 2019, Clinical Pharmacokinetics.

A randomized phase 2 trial of azacitidine with or without durvalumab as first-line therapy for higher-risk myelodysplastic syndromes

M. Tormo, M. Voso, J. Cavenagh, 2021, Blood advances.

An international, biomarker-directed, randomized, phase II trial of AZD1775 plus paclitaxel and carboplatin (P/C) for the treatment of women with platinum-sensitive, TP53-mutant ovarian cancer.

A. Oza, R. Wenham, D. Provencher, 2015 .

Phase II study with Wee1 inhibitor AZD1775 plus carboplatin in patients with p53 mutated ovarian cancer refractory or resistant (<3 months) to standard first line therapy.

D. Jong, J. Schellens, J. Beijnen, 2015 .

Fedratinib (FEDR) in myelofibrosis (MF) patients previously treated with ruxolitinib (RUX): A reanalysis of the JAKARTA-2 study.

S. Verstovsek, T. Gerike, R. Mesa, 2019, Journal of Clinical Oncology.

Efficacy and safety of luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): interim analysis of a phase 3, open-label, randomised controlled trial

G. Garcia-Manero, S. Paolini, P. Fenaux, 2023, The Lancet.

Pharmacodynamic evaluation of pCDC2 as the target engagement biomarker to assess activity of MK-1775 a Wee1 tyrosine kinase inhibitor.

A. Oza, G. Shapiro, J. Schellens, 2012 .